Intima-media thickness, myocardial perfusion and laboratory risk factors of atherosclerosis in patients with breast cancer treated with anthracycline-based chemotherapy
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Anthracyclines adverse effects MeSH
- Atherosclerosis blood complications epidemiology MeSH
- Adult MeSH
- Carotid Intima-Media Thickness MeSH
- Tomography, Emission-Computed, Single-Photon MeSH
- Carcinoma complications drug therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Myocardium pathology MeSH
- Breast Neoplasms complications drug therapy MeSH
- Antineoplastic Combined Chemotherapy Protocols adverse effects MeSH
- Risk Factors MeSH
- Tunica Intima pathology MeSH
- Tunica Media pathology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Anthracyclines MeSH
An increased incidence of complications of atherosclerosis has been noted in cancer survivors. The aim of the present study was to evaluate, in patients with breast carcinoma, the effect of antracycline-based chemotherapy on carotid intima-media thickness (IMT), myocardial perfusion, assessed by single-photon emission tomography (SPECT) and laboratory parameters associated with the risk of atherosclerosis. Thirty-six patients with breast cancer were evaluated before and after anthracycline-based chemotherapy. Retinol, alpha-tocopherol, glycosylated hemoglobin and urinary neopterin were measured by high-performance liquid chromatography. Peripheral blood cell count, D-dimers, fibrinogen, antithrombin, glucose, magnesium, creatinine, uric acid, albumin, C-reactive protein, lipoprotein (a), cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, homocysteine, urinary albumin and N-acetyl-beta-D-glucosaminidase (NAG) were determined with routine methods. No significant differences were observed between patients and 16 controls. Compared to the measurement before the start of therapy, peripheral blood leukocyte and platelet count, hemoglobin, creatinine, HDL cholesterol, retinol, albumin, urinary albumin and NAG decreased, and total cholesterol, LDL cholesterol, triglycerides, neopterin and mean IMT increased significantly after the treatment. Of the 36 patients who had SPECT after treatment, perfusion defects were noted only in two cases, including the patient who had perfusion defects at baseline examination and a patient who did not have a baseline SPECT. In conclusion, a significant increase in carotid IMT, total cholesterol, LDL cholesterol, triglycerides and urinary neopterin and a decrease of peripheral blood leukocyte and platelet counts, hemoglobin, creatinine, HDL cholesterol, retinol, albumin and NAG were observed after the treatment.
See more in PubMed
Adv Intern Med. 2000;45:391-418 PubMed
Clin Chem. 2009 Jun;55(6):1135-46 PubMed
Ann Intern Med. 1994 Jan 15;120(2):104-10 PubMed
Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):508-16 PubMed
Eur J Cancer. 2005 May;41(7):1026-30 PubMed
J Clin Oncol. 2005 Dec 20;23(36):9130-7 PubMed
Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1023-8 PubMed
Tex Heart Inst J. 2009;36(3):205-13 PubMed
J Intern Med. 2005 Aug;258(2):124-32 PubMed
J Clin Oncol. 2004 Feb 15;22(4):640-7 PubMed
J BUON. 2006 Oct-Dec;11(4):505-9 PubMed
Am J Cardiol. 2002 Oct 15;90(8):827-32 PubMed
J Clin Oncol. 2000 Apr;18(8):1725-32 PubMed
J Clin Oncol. 2003 Apr 15;21(8):1513-23 PubMed
Am Heart J. 2004 Jun;147(6):1093-9 PubMed
Scand J Clin Lab Invest. 1995 Apr;55(2):149-52 PubMed
Br J Nutr. 2005 Feb;93(2):153-74 PubMed
Anticancer Res. 2008 Jul-Aug;28(4C):2389-96 PubMed
Cancer. 2007 Feb 15;109(4):650-7 PubMed
Anticancer Res. 2009 Nov;29(11):4813-20 PubMed
J Med. 1995;26(5-6):221-33 PubMed
Circulation. 2002 Dec 3;106(23):2925-9 PubMed
Circulation. 1998 Feb 17;97(6):535-43 PubMed
Eur J Cancer. 2004 Mar;40(5):701-6 PubMed
Stroke. 2002 Nov;33(11):2581-6 PubMed
Am J Cardiol. 2009 Nov 15;104(10):1383-8 PubMed
Vasc Med. 2006 Nov;11(3):201-11 PubMed
Clin Exp Immunol. 1995 Oct;102(1):217-23 PubMed
Int J Radiat Oncol Biol Phys. 1978 Sep-Oct;4(9-10):895-906 PubMed
N Engl J Med. 2005 Apr 21;352(16):1685-95 PubMed
J Exp Clin Cancer Res. 2004 Dec;23(4):579-84 PubMed
Breast Cancer Res Treat. 1996;40(3):265-70 PubMed
Clin Nutr. 2002 Apr;21(2):161-4 PubMed
J Clin Endocrinol Metab. 2006 Nov;91(11):4433-7 PubMed
J Clin Oncol. 2006 Jun 20;24(18):2779-85 PubMed
Anticancer Res. 2009 Aug;29(8):3337-46 PubMed
Ann Clin Biochem. 2004 Mar;41(Pt 2):138-41 PubMed
